Povetacicept
alpine immune sciences
['ruby', 'alpine', 'alpineimmune']
this weekend at #eha2023, allison naumovski, phd, scientific director at alpine, will give an oral presentation on ruby-1, a phase 1 study of povetacicept, our potential best-in-class dual baff/april inhibitor. view our press release: 
Modern therapies targeting the immune synapse. Founded 2015. (NASDAQ:ALPN)